Business Wire

REPLY: Roboverse Reply Drives EU-Funded Fluently Project Aiming to Enable Human-Robot Social Collaboration Using the Latest AI Advancements

12.10.2023 09:30:00 CEST | Business Wire | Press Release

Share

Reply, a global systems integrator and consulting firm, announces that Roboverse Reply, the Reply company specialising in robotics integration, is leading the EU-funded "Fluently" project. The project aims to create a platform that fosters real social collaboration between humans and robots in industrial settings by leveraging the latest advancements in AI-driven decision-making.

The goal of this three-year project is to develop a platform and a wearable device for industrial workers and robots that will allow machines to interpret speech, content and tone more accurately and convert gestures automatically into robot instructions, and to build a training centre called "Fluently RoboGym", where industrial workers and robots can train to interact smoothly in the production process.

Practical use cases for human-robot collaboration relate to future critical value chains in European industry that involve high physical loads but also high demands on human experience and skill, such as the disassembly and recycling of lithium cell batteries, inspection and maintenance processes in the aerospace industry, and the refurbishment of complex industrial parts through additive manufacturing.

Twenty-two partners are involved in the project, including the Swiss university SUPSI. Anna Valente, Head of the SUPSI Laboratory for Automation, Robotics, and Machines and a member of the Swiss Science Council, adds: "The Fluently project aims to train robots to become team players that support human workers to the best of their abilities. As scientific and technical coordinators, we conceived Fluently to become a key milestone in advanced human-robot collaboration while establishing a best practice and a proof of concept of more inclusive and interactive ecosystems."

The project has successfully completed its first year of development and achieved initial milestones. The team is now focusing on three main working packages:

- Fluently unit design, which consists in the design of Fluently’s device, software testing and integration into wearable strap and robotic systems;
- Development of AI models, which include architecture design, edge computing, Robo-Gym model training and human-robot teamwork support;
- Robo-Gym design and implementation, which consists in defining Robo-Gym specification and objectives and the development and building of three training areas.

The Fluently system will rely on innovative technologies to ensure seamless communication between humans and robots. Natural language processing, hands-free remote collaboration equipment, physiological signal monitoring and eye tracking are some of the topics that will be researched and integrated during this project.

"We are proud to coordinate the innovative Fluently project that brings together partners from both academia and industries to develop an empathetic robot platform that can interpret speech content, tone and gesture making industrial robots accessible to any skill profile," said Filippo Rizzante, CTO of Reply. "Robots equipped with Fluently will constantly support with the humans’ physical and cognitive loads, but will also learn and build experience with their human teammates."

Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Roboverse Reply
Roboverse Reply specialises in the integration scenarios around Robotics and Reality Capture with Mixed Reality, where Cloud or On-Premises Infrastructures require Enterprise-Ready solutions. Roboverse Reply solutions include AI Skills with sensor-based anomaly detection, Fleet Management for Internet of Robotic Things, Digital Twins and Business Logic to deliver end-to-end support for the customers. The Roboverse Reply platform enables Autonomous Preventive Inspection to prolong the lifespan of your infrastructures and interactive telepresence, crucial for Safety and Security purposes. www.roboverse.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Sandra Dennhardt
s.dennhardt@reply.com
Tel. +49 170 4546229

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye